Results 121 to 130 of about 19,810 (255)

Supplementary Figure S7 from Preclinical Investigation of ²¹²Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model [PDF]

, 2023
Tania A. Rozgaja Stallons, Amal Saidi, Izabela Tworowska, Ebrahim S. Delpassand, Julien Torgue   +4 more
openalex   +2 more sources

Metastatic Type 1 low-grade gastric neuroendocrine tumor treated with peptide receptor radionuclide therapy in a young adult: a case report [PDF]

, 2023
Elisabetta Dell’Unto, Maria Rinzivillo, Gianluca Esposito, Elsa Iannicelli, Daniela Prosperi, Francesco Panzuto, Bruno Annibale   +6 more
openalex   +1 more source

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

BMC Cancer, 2019
Background For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3–4 adverse events in a large number of patients. Peptide Receptor Radionuclide Therapy (PRRT), which
Carolien M. Beukhof, Tessa Brabander, Francien H. van Nederveen, Marie-Louise F. van Velthuysen, Yolanda B. de Rijke, Leo J. Hofland, Gaston J. H. Franssen, Lideke A. C. Fröberg, Boen L. R. Kam, W. Edward Visser, Wouter W. de Herder, Robin P. Peeters   +11 more
doaj   +1 more source

Cutaneous Neuroendocrine Metastases of Visceral Origin Responsive to Surgical Resection and Targeted Radionuclide Therapy

Case Reports in Dermatological Medicine
Neuroendocrine neoplasms (NENs) encompass a diverse range of biologically and behaviorally distinct epithelial malignancies that derive from neuroendocrine cells. These neoplasms are able to secrete a variety of bioactive amines or peptide hormones.
Eleanor Tung-Hahn, Ghassan El-Haddad, Jonathan Strosberg   +2 more
doaj   +1 more source

Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis [PDF]

, 2021
Emmanouil Alevroudis, Maria-Eleni Spei, Sofia Chatziioannou, Marina Tsoli, Göran Wallin, Gregory Kaltsas, Kosmas Daskalakis   +6 more
openalex   +1 more source

Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates [PDF]

, 2021
Peter Staanum, Anders Floor Frellsen, Marie Louise Olesen, Peter Iversen, Anne Kirstine Arveschoug   +4 more
openalex   +1 more source

Tolerability and outcomes of neuroendocrine tumors treated with PRRT and SBRT

Endocrine Oncology
There is interest in optimizing peptide receptor radionuclide therapy (PRRT) for the management of metastatic neuroendocrine neoplasms (NEN). The addition of stereotactic body radiation therapy (SBRT) may provide synergistic benefits by targeting ...
Jose E Nunez, Sylvia Ng, Hanbo Chen, Simron Singh, Julie Hallet, Calvin Law, Sten Myrehaug   +6 more
doaj   +1 more source

Potentially fatal crisis after 177Lu-DOTATATE therapy for paraganglioma: a case report with review of literature

Endocrine Journal
Pheochromocytoma/paraganglioma (PPGL) is a rare neuroendocrine tumor with metastatic potential. Peptide receptor radionuclide therapy with 177Lu-DOTATATE, a radiolabeled somatostatin analog, has been used for the treatment of somatostatin receptor ...
Aoki Tobimatsu, Kosuke Mukai, Yoshinari Obata, Kayako Isohashi, Kazuyuki Miyashita, Atsunori Fukuhara, Hiroki Kato, Iichiro Shimomura   +7 more
doaj   +1 more source

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? [PDF]

, 2018
Purpose: Gallium-68 is a metallic positron emitter with a half-life of 68min that is ideal for the in vivo use of small molecules, such as [68Ga-DOTA,Tyr3]octreotide, in the diagnostic imaging of somatostatin receptor-positive tumours.
Antunes, P., Baum, R., Ginj, M., Maecke, H., Reubi, J., Waser, B., Zhang, H.   +6 more
core  

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours [PDF]

, 2013
Lisa Bodei, Jan Mueller‐Brand, Richard P. Baum, Marianne E. Pavel, Dieter Hörsch, M. Sue O’Dorisio, Thomas M. O’Dorisio, James R. Howe, Marta Cremonesi, D. J. Kwekkeboom, John J. Zaknun   +10 more
openalex   +1 more source